Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

Andrea R. Shiakolas; Kevin J. Kramer; Nicole V. Johnson; Steven C. Wall; Naveenchandra Suryadevara; Daniel Wrapp; Sivakumar Periasamy; Kelsey A. Pilewski; Nagarajan Raju; Rachel Nargi; Rachel E. Sutton; Lauren M. Walker; Ian Setliff; James E. Crowe; Alexander Bukreyev; Robert H. Carnahan; Jason S. McLellan; Ivelin S. Georgiev

doi:10.1038/s41587-022-01232-2

Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

Andrea R. Shiakolas, Kevin J. Kramer, Nicole V. Johnson, Steven C. Wall, Naveenchandra Suryadevara, Daniel Wrapp, Sivakumar Periasamy, Kelsey A. Pilewski, Nagarajan Raju, Rachel Nargi, Rachel E. Sutton, Lauren M. Walker, Ian Setliff, James E. Crowe, Alexander Bukreyev, Robert H. Carnahan, Jason S. McLellan, Ivelin S. Georgiev

Pathology

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.

Original language	English (US)
Pages (from-to)	1270-1275
Number of pages	6
Journal	Nature Biotechnology
Volume	40
Issue number	8
DOIs	https://doi.org/10.1038/s41587-022-01232-2
State	Published - Aug 2022

ASJC Scopus subject areas

Biotechnology
Bioengineering
Applied Microbiology and Biotechnology
Molecular Medicine
Biomedical Engineering

Access to Document

10.1038/s41587-022-01232-2

Cite this

Shiakolas, A. R., Kramer, K. J., Johnson, N. V., Wall, S. C., Suryadevara, N., Wrapp, D., Periasamy, S., Pilewski, K. A., Raju, N., Nargi, R., Sutton, R. E., Walker, L. M., Setliff, I., Crowe, J. E., Bukreyev, A., Carnahan, R. H., McLellan, J. S., & Georgiev, I. S. (2022). Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nature Biotechnology, 40(8), 1270-1275. https://doi.org/10.1038/s41587-022-01232-2

Shiakolas, AR, Kramer, KJ, Johnson, NV, Wall, SC, Suryadevara, N, Wrapp, D, Periasamy, S, Pilewski, KA, Raju, N, Nargi, R, Sutton, RE, Walker, LM, Setliff, I, Crowe, JE, Bukreyev, A, Carnahan, RH, McLellan, JS & Georgiev, IS 2022, 'Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking', Nature Biotechnology, vol. 40, no. 8, pp. 1270-1275. https://doi.org/10.1038/s41587-022-01232-2

@article{af4af42893d94b0a852ea7ec9264a4d1,

title = "Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking",

abstract = "Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.",

author = "Shiakolas, {Andrea R.} and Kramer, {Kevin J.} and Johnson, {Nicole V.} and Wall, {Steven C.} and Naveenchandra Suryadevara and Daniel Wrapp and Sivakumar Periasamy and Pilewski, {Kelsey A.} and Nagarajan Raju and Rachel Nargi and Sutton, {Rachel E.} and Walker, {Lauren M.} and Ian Setliff and Crowe, {James E.} and Alexander Bukreyev and Carnahan, {Robert H.} and McLellan, {Jason S.} and Georgiev, {Ivelin S.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2022",

month = aug,

doi = "10.1038/s41587-022-01232-2",

language = "English (US)",

volume = "40",

pages = "1270--1275",

journal = "Nature Biotechnology",

issn = "1087-0156",

publisher = "Nature Research",

number = "8",

}

TY - JOUR

T1 - Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

AU - Shiakolas, Andrea R.

AU - Kramer, Kevin J.

AU - Johnson, Nicole V.

AU - Wall, Steven C.

AU - Suryadevara, Naveenchandra

AU - Wrapp, Daniel

AU - Periasamy, Sivakumar

AU - Pilewski, Kelsey A.

AU - Raju, Nagarajan

AU - Nargi, Rachel

AU - Sutton, Rachel E.

AU - Walker, Lauren M.

AU - Setliff, Ian

AU - Crowe, James E.

AU - Bukreyev, Alexander

AU - Carnahan, Robert H.

AU - McLellan, Jason S.

AU - Georgiev, Ivelin S.

PY - 2022/8

Y1 - 2022/8

N2 - Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.

AB - Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.

UR - http://www.scopus.com/inward/record.url?scp=85125528531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125528531&partnerID=8YFLogxK

U2 - 10.1038/s41587-022-01232-2

DO - 10.1038/s41587-022-01232-2

M3 - Article

C2 - 35241839

AN - SCOPUS:85125528531

SN - 1087-0156

VL - 40

SP - 1270

EP - 1275

JO - Nature Biotechnology

JF - Nature Biotechnology

IS - 8

ER -

Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this